Cite
APA Citation
Burmester, G. R., McInnes, I. B., Kremer, J., Miranda, P., Korkosz, M., Vencovsky, J., Rubbert-Roth, A., Mysler, E., Sleeman, M. A., Godwood, A., Sinibaldi, D., Guo, X., White, W. I., Wang, B., Wu, C., Ryan, P. C., Close, D., & Weinblatt, M. E. (2017). a randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. Annals of the rheumatic diseases, 76(6), 1020–1030. http://access.bl.uk/ark:/81055/vdc_100137792097.0x000057